TEL AVIV, Israel and BETHESDA, Maryland, Jan. 9, 2020 /PRNewswire/ — Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that in a pre-clinical study held at the company’s High Throughput Screening (HTS) lab facilities in Israel, preliminary findings show that the cannabinoid Cannabigerol (CBG) was shown to have a greater anti-tumor effect on human stomach and bone cancer cell lines compared to CBGA, the acidic form of the compound.

CBG is a non-psychoactive cannabinoid found in minute quantities in the raw cannabis plant. Also known as the “mother” cannabinoid, other cannabinoids such as THC, CBD, CBN and CBC are synthesized from CBG. It is anecdotally known to show promise in having anti-inflammatory qualities and may act as an antibacterial agent.

In the current experiment, the HTS platform was utilized to screen the necrotic effects of both CBG & CBGA on various types of cancer cell lines. Interestingly, CBG was found to induce necrotic effects while CBGA had no such effect.

These findings further support previous research performed by the company, which has consistently shown differential anti-tumor effects when using a variety of cannabinoids on human cancer cells, derived from both fresh biopsies and cell lines.

These preliminary findings could allow Cannabics Pharmaceuticals to offer in the future, pending further research, a more extensive and thorough personalized report for patients advising them on cannabinoid medicine therapy protocols in order to maximize positive outcomes.

Dr. Yaakov Waksman, the company’s Head of Cannabidiol Research, said: “CBG is gaining a lot of interest as of late by the scientific community due to its potential therapeutic properties. The recent preliminary findings from our research team illustrate how purified cannabinoids can potentially yield anti-tumor activity and enable us to examine the entourage effect of botanical extracts versus the purified compounds. We are excited by these preliminary findings and plan to perform additional experiments in the near future to further support them.”

About Cannabics Pharmaceuticals

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) is a U.S. public company that is developing a platform which leverages novel drug-screening tools and artificial intelligence to create cannabinoid-based therapies for cancer that are more precise to a patient’s profile. By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move cannabinoids into the future of cancer therapy. The company’s R&D is based in Israel, where it is licensed by the Ministry of Health to conduct scientific and clinical research on cannabinoid formulations and cancer.

For the latest updates on Cannabics Pharmaceuticals follow the company on [email protected], [email protected], LinkedIn, and on Instagram @Cannabics_Pharmaceuticals.

Disclaimer:

Certain statements contained in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other U.S. Federal securities laws. Such statements include but are not limited to statements identified by words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission including, without limitation, our latest 10-K Report filed on November 29th, 2019. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information about Cannabics Pharmaceuticals Inc. which are condoned by the Company must emanate from the Company itself and bear our name as its source.